Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-10. (Cancelled)

11. (Previously Presented) A compound of formula (Ij):



(Ij)

wherein:

R^1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-6}alkylene-Y-, and heterocyclylC_{0-6}alkylene-Y-; or two R^1 groups on adjacent carbons may form an oxyC_{1-4}alkoxy group or a C_{3-5}alkylene group; wherein R^1 may be optionally substituted on carbon with one or more R^7 groups; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by an R^8 group;

n is 0-3; wherein the values of R^1 may be the same or different;

R^2 and R^3 are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, C_{1-4}alkoxycarbonylamino, C_{1-4}alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC_{1-4}alkyl, and heterocyclylC_{1-4}alkyl; or

R^2 and R^3 together form oxo or a spiro attached heterocyclyl; wherein R^2 and R^3 may be independently optionally substituted on carbon with one or more R^9 groups; and wherein if said

heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted with an R^{10} group;

Ring B is a heterocyclyl linked to the sulphonyl of the compound of formula **(Ij)** via a nitrogen atom; wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted with an R^{17} group;

$\mathbf{R^6}$ is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-4}alkylene-Y-, and heterocyclylC_{0-4}alkylene-Y-; wherein R^6 may be optionally substituted on carbon with one or more R^{18} groups; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted with an R^{19} group;

m is 0-3; wherein the values of R^6 may be the same or different;

Y is -S(O)$_a$-, -O-, -NR^{20}-, -C(O)-, -C(O)NR^{21}-, -NR^{22}C(O)-, or -SO$_2$NR^{23}-; wherein a is 0 to 2;

$\mathbf{R^7}$, $\mathbf{R^9}$, and $\mathbf{R^{18}}$ are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, and heterocyclyl; wherein R^7, R^9, and R^{18} may be independently optionally substituted on carbon with one or more R^{26} groups;

$\mathbf{R^8}$, $\mathbf{R^{10}}$, $\mathbf{R^{17}}$, and $\mathbf{R^{19}}$ are independently selected from C_{1-4}alkyl, C_{1-4}alkanoyl, C_{1-4}alkylsulphonyl, C_{1-4}alkoxycarbonyl, carbamoyl, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl, and phenylsulphonyl; wherein R^8, R^{10}, R^{17}, and R^{19} may be independently optionally substituted on carbon with one or more R^{27} groups;

R^{20}, R^{21}, R^{22}, and R^{23} are independently selected from hydrogen, phenyl, C_{1-4}alkylsulphonyl, and C_{1-4}alkyl;

R^{26} and R^{27} are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, and *N*-methyl-*N*-ethylsulphamoyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not (phenyl)-[α-(pyrrolidin-1-ylsulphonyl)benzyl]-ketone;

(phenyl)-[α-(morpholinosulphonyl)benzyl]-ketone;

(4-carbamoylphenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-1-ylsulphonylmethyl]-ketone;

(4-carbamoylphenyl)-[4-(4-fluorophenyl)piperidin-1-ylsulphonylmethyl]-ketone;

(4-fluorophenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-1-ylsulphonylmethyl]-ketone;

(phenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-1-ylsulphonylmethyl]-ketone;

(4-chlorophenyl)-(piperazin-1-ylsulphonylmethyl)-ketone;

(4-chlorophenyl)-[4-(*t*-butoxycarbonyl)piperazin-1-ylsulphonylmethyl]-ketone;

(4-hydroxyphenyl)-(morpholinosulphonylmethyl)-ketone; or

(phenyl)-(1,2,3,4-tetrahydroisoquinolin-2-ylsulphonylmethyl)-ketone;

when R^2 and R^3 are hydrogen, m is 0, and Ring B is 4-methylpiperazin-1-yl, then $(R^1)_n$ is not hydrogen, 4-fluoro, 4-nitro, 3,4-dimethoxy, 4-methoxy, 4-*t*-butyl, 4-trifluoromethyl, or 4-chloro; and

when R^2 and R^3 are hydrogen, m is 0, and Ring B is morpholino, then $(R^1)_n$ is not hydrogen, 4-dimethylamino, 4-nitro, 4-methoxy, 4-*t*-butyl, 4-trifluoromethyl, or 4-fluoro or 4-chloro.

12. (Cancelled)

13. (Currently Amended) A pharmaceutical composition which comprises a compound of claim 11 ~~any one of claims 9, 11 or 12~~, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.

14-20. (Cancelled)

21. (New) The compound of claim 11, wherein the compound is (morpholinosulphonylmethyl)-(4-fluorophenyl)-ketone.

22. (New) A method for inhibiting 11βHSD1, comprising administering a compound of claim 11.

23. (New) The method of claim 22, wherein a therapeutically effective amount of the compound is administered to a warm-blooded animal.

23. (New) The method of claim 22, wherein the method is a method of treating a disease.

24. (New) The method of claim 23, wherein the disease is a metabolic syndrome.

25. (New) The method of claim 23, wherein the disease is selected from diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia, and hypertension.

26. (New) The method of claim 23, wherein the disease is selected from glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.

27. (New) A method for inhibiting 11βHSD1, comprising administering the composition of claim 13.

28. (New) The method of claim 27, wherein a therapeutically effective amount of the composition is administered to a warm-blooded animal.

29. (New) The method of claim 27, wherein the method is a method of treating a disease.

30. (New) The method of claim 29, wherein the disease is a metabolic syndrome.

31. (New) The method of claim 29, wherein the disease is selected from diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia, and hypertension.

32. (New) The method of claim 29, wherein the disease is selected from glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.